New compounds

A compound having the formula I:

• where R1 and R2 are independently halo or C1-3haloalkyl,
• X is ethenyl or ethynyl,
• or a pharmaceutically acceptable salt thereof,
• for use as a medicament for treatment of VR1 mediated disorders.

Use of a compound having the formula I:

• where R1 and R2 are independently halo or C1-3haloalkyl,
• X is ethenyl or ethynyl,
• or a salt thereof,
• in the manufacture of a medicament,
• with the proviso that the compound is not 1′-[(2E)-3-(3,4-dichlorophenyl)prop-2-en-1-yl]-2H,5H-spiro[imidazolidine-4,3′-indole]-2,2′,5 (1′H)-trione in racemic form.

Use of a compound having the formula I:

• where R1 and R2 are independently halo or C1-3haloalkyl,
• X is ethenyl or ethynyl,
• or a salt thereof,
• in the manufacture of a medicament for treatment of VR1 mediated disorders.

A compound selected from the group consisting of

• 1-Allyl-1H-indole-2,3-dione,
• 1-[(2E)-3-(3,4-dichlorophenyl)prop-2-en-1-yl]-1H-indole-2,3-dione,
• 1-{(2E)-3-[4-chloro-3-(trifluoromethyl)phenyl]prop-2-en-1-yl}-1H-indole-2,3-dione,
• 1-prop-2-yn-1-yl-1H-indole-2,3-dione, and
• 1-[3-(3,4-dichlorophenyl)prop-2-yn-1-yl]-1H-indole-2,3-dione

A process for preparing a compound of formula III

• where R1 and R2 are independently halo or C1-3haloalkyl,
• X is ethenyl or ethynyl, comprising:
• Reaction of an optionally protected compound of formula IV
• with
• where HAL is an halogen atom, in the presence of a suitable palladium catalyst, such as Pd(P(t-Bu)3)2 or Pd(OAc)2, in a suitable solvent,
• and thereafter optionally:
• ii) converting the intermediate of formula III into another intermediate of formula III;
• and/or
• iii) removing any protecting groups.